TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02342860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WASH in Schools (WinS) programme
Description: The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package.
Study: NCT00395070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allovectin-7®
Description: Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine (DTIC)
Description: 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
Study: NCT04657445

Intervention type: DIAGNOSTIC_TEST
Intervention: visual analogue scale
Description: A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
Study: NCT02795624

Intervention type: PROCEDURE
Intervention: Spirometry
Description: Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.

Intervention type: PROCEDURE
Intervention: Pulse Wave Analysis
Description: It is a non-invasive assessment of the pulse character

Intervention type: PROCEDURE
Intervention: Peripheral arterial tonometry
Description: It is a non-invasive method to measure endothelial dysfunction.
Study: NCT01921556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active comparator, QualiCCare education
Description: Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support.
Study: NCT02016391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
Study: NCT04245449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAACH
Description: TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities.
Study: NCT02998879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velmanase Alfa (e.g. Lamazym)
Description: iv infusion treatment
Study: NCT04931914

Intervention type: OTHER
Intervention: Clinical pharmacy sharing in the patient care regimen
Description: antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
Study: NCT01496287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube Delivery System (TDS)
Description: Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
Study: NCT00861757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO, QD (30 min after meal) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: PO, QD (30 min after meal) for 12 weeks
Study: NCT04342416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visiospatial Interference
Description: Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
Study: NCT00696098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium butyrate
Description: 1 enema (60 ml) once daily containing 100mM
Study: NCT03025477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC0 - Carboplatin (IV) - Paclitaxel (IV)
Description: (6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC0 - Cisplatin (IP) - Epirubicin (IV)
Description: (6 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC>0 - Carboplatin (IV)- Paclitaxel (IV)
Description: * carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
Description: * Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)
Study: NCT03569449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based visits and community visits
Description: In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
Study: NCT01525862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation
Study: NCT03047811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCR - T cell therapy
Description: Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
Study: NCT04015570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Volume Plasma Exchange
Description: PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment (Albumin+High caloric diet)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment (Albumin+High caloric diet)
Study: NCT03419312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proclaim™ Elite 5: Burst - Washout - Sham
Description: All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proclaim™ Elite 5: Sham - Washout - Burst
Description: All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106.
Study: NCT03353038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed pillbox
Description: The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
Study: NCT02805465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Device and Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT Device and Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Device and His-bundle Pacing
Description: His-bundle pacing by a CRT device through the pacing lead at His-bundle region

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT Device and His-bundle Pacing
Description: His-bundle pacing by a CRT device through the pacing lead at His-bundle region
Study: NCT00931125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab and vitrectomy
Description: ranibizumab 10mg/ml intravitreal injection, 0,05 ml

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: vitrectomy without preoperative ranibizumab
Description: sham intravitreal injection before vitrectomy surgery
Study: NCT02584062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch fluid-air exchange
Study: NCT00696098

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 1 enema (60 ml) once daily containing 0.9%NaCl
Study: NCT01181141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b (edoxaban)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium 20mg
Study: NCT02582931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided SBRT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 Questionnaire
Description: 30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-OV28 Questionnaire
Description: 28 questions having answers that range from 1 (not at all) to 4 (very much)
Study: NCT04368000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent prone positioning instructions
Description: Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care positioning with no instructions
Description: Participants will not be given instructions to lie in the prone position for any duration.
Study: NCT01909219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium picosulphate/magnesium Citrate
Description: Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium picosulphate/magnesium Citrate
Description: Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
Study: NCT04321278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + azithromycin
Description: Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Study: NCT02584062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy metrectomy and internal membrane peeling and gas tamponed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy metrectomy and internal membrane peeling and gas tamponed
Study: NCT00000407

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocational counseling intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading materials for control participants

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: No education or behavioral intervention
Study: NCT04490525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
Study: NCT02789358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cryotherapy dosage
Description: Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental cryotherapy dosage
Description: cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Front Advance ST Cryoenergy Balloon Catheter
Description: Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
Study: NCT04321278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Study: NCT02288039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Identity goal-based Intervention
Description: Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
Study: NCT02789358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance ST Cryoenergy Balloon Catheter
Description: Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine triphosphate
Description: 12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
Study: NCT04358289

Intervention type: OTHER
Group type: OTHER
Intervention: Basic antimicrobial stewardship education
Description: Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines

Intervention type: OTHER
Group type: OTHER
Intervention: Basic antimicrobial stewardship education
Description: Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines

Intervention type: OTHER
Group type: OTHER
Intervention: Participatory action research group in commune health center and community
Description: * Establish a participatory action research group~* Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: Antimicrobial stewardship program in hospitals
Description: The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies
Study: NCT02789358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate
Description: 12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nECG platform Nuubo®
Description: 30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nECG platform Nuubo®
Description: 30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
Study: NCT01498692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
Study: NCT02658552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
Study: NCT01947283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DECIDE-PA
Description: The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DECIDE-PA
Description: The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DECIDE-PC
Description: The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
Study: NCT05664503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions STOMA-M
Description: The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
Study: NCT04507048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active educational intervention
Description: an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive educational intervention
Description: Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules.
Study: NCT03571750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Stronger Allies
Description: BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Training
Description: In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
Study: NCT03962894

Intervention type: DRUG
Intervention: Prednisolone
Description: During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
Study: NCT01642901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
Study: NCT00510445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat Sodium (GRN163L)
Description: The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle.
Study: NCT02653443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.
Description: Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
Study: NCT01445561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (100,00 IU/m(2) SQ)
Description: 100,000 International Units/m2 SQ daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (100,00 IU/m(2) SQ)
Description: 100,000 International Units/m2 SQ daily for 5 days